Last reviewed · How we verify
KX0826
At a glance
| Generic name | KX0826 |
|---|---|
| Also known as | Pyrilutamide, KX-826 |
| Sponsor | Suzhou Kintor Pharmaceutical Inc, |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- the Safety, Tolerability and PK of KX-826 in Healthy Males With Alopecia Following Topical Multiple Dose Ascending (PHASE1)
- Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KX0826 CI brief — competitive landscape report
- KX0826 updates RSS · CI watch RSS
- Suzhou Kintor Pharmaceutical Inc, portfolio CI